Article Versions Notes

Rasheed A, Zaheer AB, Munawwar A, Sarfraz Z, Sarfraz A, Robles-Velasco K, Cherrez-Ojeda I. The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review. Life. 2023; 13(1):1. https://doi.org/10.3390/life13010001

Rasheed, Anum, Ahmad Bin Zaheer, Aqsa Munawwar, Zouina Sarfraz, Azza Sarfraz, Karla Robles-Velasco, and Ivan Cherrez-Ojeda. 2023. "The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review" Life 13, no. 1: 1. https://doi.org/10.3390/life13010001

Rasheed, A., Zaheer, A. B., Munawwar, A., Sarfraz, Z., Sarfraz, A., Robles-Velasco, K., & Cherrez-Ojeda, I. (2023). The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review. Life, 13(1), 1. https://doi.org/10.3390/life13010001